Skip Navigation

European Heart Journal 2001 22(19):1808-1816; doi:10.1053/euhj.2001.2608
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wöhrle, J
Right arrow Articles by Höher, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wöhrle, J
Right arrow Articles by Höher, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Comparison of the heparin coated vs the uncoated Jostent®—no influence on restenosis or clinical outcome

J Wöhrlef1, E Al-Khayer, U Grötzinger, C Schindler, M Kochs, V Hombach and M Höher

Department of Cardiology, University of Ulm, Ulm, Germany

revised January 16, 2001; accepted January 17, 2001

Abstract

Aims Heparin coating of stents is thought to reduce stent thrombosis and restenosis rates. However, clinical data comparing coated and uncoated stents of the same model are lacking. We compared the heparin coated (C) and the uncoated (U) version of the Jostent®stent with regard to the clinical and angiographic outcome after 6 months.

Methods and Results Provisional stenting was done in 277 patients and 306 lesions; only 40 were Benestent-II like lesions. Delivery success rate was 98·4%. Both groups (C/U: n=156/150 lesions) were comparable in clinical and procedural data. Post stenting, reference diameter (C/U: 2·68±0·56/2·66±0·53mm) and minimal lumen diameter did not differ (C/U: 2·48±0·47/2·48±0·52mm). During follow-up the rate of subacute stent thrombosis (C/U: 1·9%/1·3%) and myocardial infarction did not differ. Angiography at the 6-month follow-up (79·4%) revealed no difference in restenosis rate (C/U: 33·1%/30·3%). Risk factors for restenosis were a type B2/C lesion (P<0·02), a stented segment longer than 16mm (P<0·006) and a stent inflation pressure <14 bar (P<0·0063).

Conclusion Corline heparin coating of the Jostent®has no impact on the in-hospital complication rate, stent thrombosis or restenosis. The Jostent®design gives a high procedural success rate and satisfying result at 6 months in an everyday patient population undergoing provisional stenting.

Key Words: Stent, restenosis, heparin coating, thrombosis

f1 Correspondence: Martin Höher, MD, FESC, University of Ulm, Department of Cardiology, Robert-Koch-Straße 8, 89081 Ulm, Germany.

References

  1. Mintz GS, Popma JJ, Hong MK. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol. 1996;78:18–22[CrossRef][ISI][Medline]
  2. Berger PB, Bell MR, Rihal CS. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol. 1999;34:1891–1894[Abstract/Free Full Text]
  3. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667–1672[Abstract/Free Full Text]
  4. De SI, Wang K, Wilczek K. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation. 1997;95:1549–1553[Abstract/Free Full Text]
  5. Blezer R, Cahalan L, Cahalan PT, Lindhout T. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation. Blood Coagul Fibrinolysis. 1998;9:435–440[ISI][Medline]
  6. Serruys, PW, van Hout, B, Bonnier, H, Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) [published erratum appears in Lancet, 1998, 352, 1478, Lancet, 1998, 352, 673, 81
  7. van der Giessen WJ, van Beusekom HM, Eijgelshoven MH, Morel MA, Serruys PW. Heparin-coating of coronary stents. Semin Interv Cardiol. 1998;3:173–176[Medline]
  8. Vrolix MCM, Legrand V, Reiber JHC. Heparin-Coated Wiktor Stents in Human Coronary Arteries (MENTOR Trial). Am J Cardiol. 2000;86:385–389[CrossRef][ISI][Medline]
  9. Van Langenhove G, Vermeersch P, Serrano P. Saphenous vein graft disease treated with the wiktor hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up. Can J Cardiol. 2000;16:473–480[ISI][Medline]
  10. Bickel C, Rupprecht HJ, Darius H. Reduction of Platelet Adherence by Different Coatings of Coronary Stents. Eur Heart J. 1999;20:272
  11. Serruys, PW, Emanuelsson, H, van der, GW, Heparin-coated Palmaz–Schatz stents in human coronary arteries, Early outcome of the Benestent-II Pilot Study, Circulation, 1996, 93, 412, 22
  12. Kohno M, Yokokawa K, Yasunari K. Heparin inhibits human coronary artery smooth muscle cell migration. Metabolism. 1998;47:1065–1069[CrossRef][ISI][Medline]
  13. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res. 1986;58:839–845[Abstract/Free Full Text]
  14. Yang Z, Birkenhauer P, Julmy F. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J Controlled Release. 1999;60:269–277[CrossRef][ISI][Medline]
  15. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625–626[CrossRef][Medline]
  16. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr., King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989;117:777–782[CrossRef][ISI][Medline]
  17. Brack MJ, Ray S, Chauhan A. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J Am Coll Cardiol. 1995;26:947–954[Abstract]
  18. Gunn J, Cumberland D. Stent coatings and local drug delivery. State of the art. Eur Heart J. 1999;20:1693–1700[Free Full Text]
  19. Harlan JM, Thompson PJ, Ross RR, Bowen-Pope DF. Alpha-thrombin induces release of platelet-derived growth factor-like molecule(s) by cultured human endothelial cells. J Cell Biol. 1986;103:1129–1133[Abstract/Free Full Text]
  20. Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA. 1975;72:131–135[Abstract/Free Full Text]
  21. Pukac L, Huangpu J, Karnovsky MJ. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res. 1998;242:548–560[CrossRef][ISI][Medline]
  22. Hedin U, Frebelius S, Sanchez J, Dryjski M, Swedenborg J. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. Arterioscler Thromb. 1994;14:254–260[Abstract/Free Full Text]
  23. Hirsh J. Heparin. N Engl J Med. 1991;324:1565–1574[ISI][Medline]
  24. Ragosta M, Karve M, Brezynski D. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. Am Heart J. 1999;137:250–257[CrossRef][ISI][Medline]
  25. Fernandez F, N'guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res. 1986;43:491–495[CrossRef][ISI][Medline]
  26. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980;46:625–634[Free Full Text]
  27. Stone GW, Brodie BR, Griffin JJ. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548–1554[Abstract/Free Full Text]
  28. Hardhammar PA, van Beusekom HM, Emanuelsson HU. Reduction in thrombotic events with heparin-coated Palmaz–Schatz stents in normal porcine coronary arteries. Circulation. 1996;93:423–430[Abstract/Free Full Text]
  29. Bertrand ME, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597–1603[Abstract/Free Full Text]
  30. Ahn YK, Jeong MH, Kim JW. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter Cardiovasc Interv. 1999;48:324–330[CrossRef][ISI][Medline]
  31. Bartorelli AL, De Cesare NB, Kaplan AV. Local heparin delivery prior to coronary stent implantation: acute and six-month clinical and angiographic results. Cathet Cardiovasc Diagn. 1997;42:313–320[CrossRef][ISI][Medline]
  32. Camenzind E, Kint PP, Di Mario C. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. Circulation. 1995;92:2463–2472[Abstract/Free Full Text]
  33. Fischman DL, Leon MB, Baim DS. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501[Abstract/Free Full Text]
  34. Di Mario C, Reimers B, Almagor Y. Procedural and follow-up results with a new balloon expandable stent in unselected lesions. Heart. 1998;79:234–241[Abstract/Free Full Text]
  35. Lau KW, Ding ZP, Johan A, Hung JS. Mid-term clinical and angiographic follow-up outcome after placement of a new balloon expandable stent in native coronary arteries. Catheter Cardiovasc Interv. 2000;49:348–351[CrossRef][ISI][Medline]
  36. Kasaoka S, Tobis JM, Akiyama T. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol. 1998;32:1630–1635[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
R Lowe, I B A Menown, G Nogareda, and I M Penn
Coronary stents: in these days of climate change should all stents wear coats?
Heart, June 1, 2005; 91(suppl_3): iii20 - iii23.
[Full Text] [PDF]

Home page
 RadiologyHome page
K. Schurmann, J. Lahann, P. Niggemann, B. Klosterhalfen, J. Meyer, A. Kulisch, D. Klee, R. W. Gunther, and D. Vorwerk
Biologic Response to Polymer-coated Stents: In Vitro Analysis and Results in an Iliac Artery Sheep Model
Radiology, January 1, 2004; 230(1): 151 - 162.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. H. Wilson, P. Fasseas, J. L. Orford, R. J. Lennon, T. Horlocker, N. E. Charnoff, S. Melby, and P. B. Berger
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting
J. Am. Coll. Cardiol., July 16, 2003; 42(2): 234 - 240.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Hoher, J. Wohrle, M. Wohlfrom, J. Kamenz, T. Nusser, O. C. Grebe, H. Hanke, M. Kochs, S. N. Reske, V. Hombach, et al.
Intracoronary {beta}-Irradiation With a Rhenium-188-Filled Balloon Catheter: A Randomized Trial in Patients With De Novo and Restenotic Lesions
Circulation, June 24, 2003; 107(24): 3022 - 3027.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Haude, T. F.M. Konorza, U. Kalnins, A. Erglis, K. Saunamaki, H. D. Glogar, E. Grube, R. Gil, A. Serra, H. G. Richardt, et al.
Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients
Circulation, March 11, 2003; 107(9): 1265 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. N. Babapulle and M. J. Eisenberg
Coated Stents for the Prevention of Restenosis: Part II
Circulation, November 26, 2002; 106(22): 2859 - 2866.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Kastrati, H. Schuhlen, and A. Schomig
Stenting for small coronary vessels: a contestable winner
J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1604 - 1607.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P.J. de Feyter
The quest for the ideal stent
Eur. Heart J., October 1, 2001; 22(19): 1766 - 1768.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wöhrle, J
Right arrow Articles by Höher, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wöhrle, J
Right arrow Articles by Höher, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?